Similar to neoadjuvant or window-of-opportunity trials in early-stage disease (66, 67), IDO inhibitors are under evaluation in several diseases to primarily determine the pathologic effect in the tumor by collecting pre- and post-treatment tissue materials (68, 69). The gene discussed is IDO1; the disease is neoplasm.